Published by Global Banking & Finance Review®
Posted on July 1, 2025
1 min readLast updated: January 23, 2026
Add as preferred source on GoogleThe European Commission approved Vertex's new cystic fibrosis drug Alyftrek, targeting patients aged 6 and older with specific gene mutations.
(Reuters) -Vertex said on Tuesday that its next-generation drug gained European Commission approval for treating cystic fibrosis, a rare and progressive genetic disease.
The approval expands the company's presence in this market as it combats weak sales of its older cystic fibrosis drug Trikafta.
The new once-daily triple combination therapy, branded Alyftrek, was approved to treat patients aged 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that responds to the therapy.
Cystic fibrosis is an inherited disorder resulting from the absence of a specific protein, which disrupts salt and water movement in and out of cells in various organs.
(Reporting by Christy Santhosh in Bengaluru; Editing by Tasim Zahid)
Vertex received European Commission approval for its next-generation drug to treat cystic fibrosis.
The new drug is branded as Alyftrek, a once-daily triple combination therapy.
Alyftrek is approved for patients aged 6 years and older with at least one F508del mutation or another mutation in the CFTR gene.
The introduction of Alyftrek aims to combat weak sales of its older cystic fibrosis drug, Trikafta.
Cystic fibrosis is an inherited disorder caused by the absence of a specific protein, disrupting salt and water movement in various organs.
Explore more articles in the Headlines category
